相关实验视频

Updated: Mar 3, 2026

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

针治疗葡萄糖代谢:对随机对照试验的更新元分析

Xinyue Jiang¹, Hui Dong², Lingling Yu²

¹Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Beijing University of Chinese Medicine, Beijing 100029, China.

Complementary therapies in medicine

|March 1, 2026

概括

针可以改善代谢障碍中的葡萄糖代谢,在胰岛素抵抗和HbA1c方面显示出好处. 然而,高异质性和方法限制需要进一步严格的试验才能得出最终的结论.

科学领域:

代谢障碍代谢障碍代谢障碍
综合医学是一个整体的医学.
葡萄糖代谢调节葡萄糖代谢调节

背景情况:

代谢障碍是一个重大的全球健康挑战.
改善葡萄糖代谢的有效管理策略至关重要.
针是一种传统疗法,具有潜在的代谢益处.

研究的目的:

评估针在改善葡萄糖代谢方面的疗效.
综合来自随机对照试验 (RCT) 关于治疗代谢障碍的证据.
确定针在管理血糖控制方面的潜在好处和局限性.

主要方法:

在多个数据库 (PubMed, Web of Science, Embase, CNKI, Wanfang) 中进行全面的文献搜索.
包括14个RCT,其中1179名参与者将针与控制干预措施进行比较.
随机效应元分析,以汇集有关血糖参数的数据.

主要成果:

针显著改善了对胰岛素抵抗 (HOMA-IR),HbA1c,禁食血葡萄糖 (FPG),2小时食后血葡萄糖 (P2hPG) 和禁食胰岛素 (FINS) 的恒温模型评估.
在聚合估计中观察到实质性的异质性.
在子组分析中,手动针似乎更有效.

结论:

针在患有代谢障碍的患者中显示出控制葡萄糖代谢的潜力.
高异质性和方法上的局限性 (偏差风险) 缓和了最终的结论.
未来需要大规模,严格设计的RCT来确认疗效并优化临床应用.

关键词:

针是一种针.葡萄糖的新陈代谢.胰岛素耐药性是一种胰岛素耐药性.进行元分析.随机对照试验是随机对照试验.

更多相关视频

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...